Female Androgenetic Alopecia: An Update on Diagnosis and Management
- PMID: 31677111
- DOI: 10.1007/s40257-019-00479-x
Female Androgenetic Alopecia: An Update on Diagnosis and Management
Abstract
Female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women. The onset may be at any age following puberty and the frequency increases with age. Clinically, it shows a diffuse hair thinning over the central scalp, while the frontal hairline is usually retained. FAGA can have a significant psychological impact, leading to anxiety and depression. For this reason, early diagnosis is very important to stop the progression of the disease. The sex hormonal milieu is the main pathogenetic mechanism studied in FAGA. The role of androgens is not clearly defined and only one-third of women with FAGA show abnormal androgen levels. Endocrinological diseases with hyperandrogenism associated with FAGA comprise polycystic ovarian syndrome (PCOS), hyperprolactinemia, adrenal hyperplasia and, rarely, ovarian and adrenal tumours. Usually the diagnosis of FAGA is made clinically. A complete clinical examination and a blood examination can reveal other signs of hyperandrogenism. Trichoscopy shows the typical hair miniaturization. A scalp biopsy can be useful when the clinical evaluation does not provide a definitive diagnosis or when cicatricial alopecias with hair loss in the distribution of FAGA or alopecia areata are suspected. FAGA is a slowly progressive disease. The goal of therapy is to stop the progression and to induce a cosmetically acceptable hair regrowth. The most important drugs are topical minoxidil and oral anti-androgens. The purpose of this review is to provide an update on FAGA and to create a guideline on diagnosis and management of this frequent hair disease, not always easily recognizable from cicatricial alopecias with a similar distribution.
Similar articles
-
A Clinico-trichological Study of Female Androgenetic Alopecia.Int J Trichology. 2021 Nov-Dec;13(6):9-16. doi: 10.4103/ijt.ijt_12_19. Epub 2021 Nov 22. Int J Trichology. 2021. PMID: 34934295 Free PMC article.
-
The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility.Australas J Dermatol. 2019 Nov;60(4):e279-e283. doi: 10.1111/ajd.13079. Epub 2019 Jun 6. Australas J Dermatol. 2019. PMID: 31168786 Review.
-
[Androgenetic alopecia in women].Cas Lek Cesk. 2017 Summer;156(3):141-144. Cas Lek Cesk. 2017. PMID: 28722458 Czech.
-
Hair loss in women.Semin Cutan Med Surg. 2009 Mar;28(1):19-32. doi: 10.1016/j.sder.2009.01.001. Semin Cutan Med Surg. 2009. PMID: 19341939 Review.
-
Management of androgenetic alopecia.J Eur Acad Dermatol Venereol. 1999 May;12(3):205-14. J Eur Acad Dermatol Venereol. 1999. PMID: 10461639 Review.
Cited by
-
Trichoscopy of Androgenetic Alopecia: A Systematic Review.J Clin Med. 2024 Mar 28;13(7):1962. doi: 10.3390/jcm13071962. J Clin Med. 2024. PMID: 38610726 Free PMC article. Review.
-
The Hormonal Background of Hair Loss in Non-Scarring Alopecias.Biomedicines. 2024 Feb 24;12(3):513. doi: 10.3390/biomedicines12030513. Biomedicines. 2024. PMID: 38540126 Free PMC article. Review.
-
Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.Skin Appendage Disord. 2023 Dec;9(6):423-437. doi: 10.1159/000531890. Epub 2023 Sep 27. Skin Appendage Disord. 2023. PMID: 38376087
-
Causal Effects of Lipids-Related Metabolites on Androgenic Alopecia: A Mendelian Randomization Study.Clin Cosmet Investig Dermatol. 2024 Feb 12;17:409-416. doi: 10.2147/CCID.S445453. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 38371329 Free PMC article.
-
Controlling Hair Loss by Regulating Apoptosis in Hair Follicles: A Comprehensive Overview.Biomolecules. 2023 Dec 22;14(1):20. doi: 10.3390/biom14010020. Biomolecules. 2023. PMID: 38254620 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical